Merith Basey will bring patients’ stories to Capitol Hill as lawmakers examine how pharmaceutical companies block competition and keep drug prices high.
WASHINGTON, D.C. — Tomorrow, Patients For Affordable Drugs Now CEO Merith Basey will testify before the Senate Judiciary Committee at its hearing, “Prescribing Sunshine: How Competition & Transparency Lowers Prescription Drug Costs.” Basey will urge Congress to advance bipartisan legislation that would curb pharmaceutical industry abuses of the patent and regulatory systems, increase competition, and lower prescription drug prices.
Across the country, patients are rationing medications, draining their savings, and going without treatments they need because of high drug prices. Basey will bring those experiences to Capitol Hill and highlight how drug companies exploit loopholes to protect their monopolies and prevent more affordable alternatives from reaching patients.
The Committee has already advanced bipartisan legislation addressing several of these practices. P4ADNow supports reforms targeting:
-
Pay-for-delay agreements: Brand-name drug companies pay potential competitors to delay bringing a lower-cost alternative to market. The Preserve Access to Affordable Generics and Biosimilars Act (S. 1096) would curtail pay-for-delay agreements and is estimated to save $1.646 billion.
-
Product hopping: Manufacturers move patients to a slightly modified version of existing drugs as generic competition approaches, undermining the market for cheaper alternatives. The Drug Competition Enhancement Act (S. 1040) would address this practice and save $1.2 billion.
-
Abuse of FDA citizen petitions: Drug companies file petitions without legitimate scientific grounds to interfere with the approval of competing medicines. The Stop STALLING Act (S. 1095) would deter these abuses and is projected to save $401 million.
-
Patent thickets: Drug companies accumulate overlapping patents around existing medicines, making it harder for generic and biosimilar competitors to enter the market. The Affordable Prescriptions for Patients Act (S. 1041) would address patent thickets that obstruct biosimilar competition.
P4AD also strongly supports the ETHIC Act (S. 2276), additional bipartisan legislation that would address patent thickets by limiting how drug companies can use certain overlapping patents in litigation to block generic and biosimilar competition. The bill is projected to save $4 billion over the next decade.
Together, these reforms would help restore greater balance to the patent system: rewarding genuine innovation while allowing competition to lower prices for patients.
Patients cannot afford to wait. Patients For Affordable Drugs Now urges Congress to advance these bipartisan solutions before the end of the year and ensure the patent system works for the people it was intended to serve — not the companies exploiting it.
###
Patients For Affordable Drugs Now is the only national, patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNow is bipartisan and does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more, visit: PatientsForAffordableDrugsNOW.org